ClinicalTrials.gg
Not yet recruitingNCT07490496Updated Oct 21, 2026

Phase 3 Bunionectomy Study

A Phase 3 interventional study of CPL-01 and saline placebo in Postoperative Pain and Bunion, sponsored by Cali Pharmaceuticals LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cali Pharmaceuticals LLC · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
356th of 1,098
112 · median 76
Started
2027
with 10 others
Phase 3
162 of 1,180
18 open now
Primary completion
2027-06
later than 138 of 235 live
Registered
1,138th of 1,180
by date

Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 356th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 11 that started in 2027, is one of 162 in phase 3, reaches primary completion later than 138 of the 235 other live ones, and was the 1,138th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,180 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

Patients with a bunion will have that repaired and then pain and rescue medicine use will be evaluated.

Read the detailed description

After signing an informed consent and then appropriate screening and meeting the inclusion and exclusion criteria, patients will have their bunion repaired under regional anesthesia. They will then stay in the facility for 72 hours while pain, rescue medication, and other criteria are assessed. A follow-up visit will occur at 7 days and 30 days after.

03

Conditions studied

  • Postoperative Pain
  • Bunion

Keywords

  • bunionectomy
  • bunion
  • osteotomy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bunion

Exclusion criteria

Exclusion Criteria:

  • Concomitant conditions
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    CPL-01

    Intra-operative local administration

    Drug: CPL-01

  • Placebo comparator
    Saline placebo

    Intra-operative local administration

    Drug: saline placebo

Interventions

  • DrugCPL-01

    Administration by the Surgeon during the operation

  • Drugsaline placebo

    Administration by the Surgeon during the operation

06

What researchers measure

Primary outcomes

  1. Postoperative Pain with activity

    AUC NRS-A wWOCF (Area Under the Curve of the Numeric Rating Scale sore for pain with Activity where 0 is no pain and 10 is worst pain imaginable)

    Time frame: 24 hours

Secondary outcomes

  1. Postoperative Pain with rest

    AUC NRS-R wWOCF (Area Under the Curve of the Numeric Rating Scale sore for pain at Rest where 0 is no pain and 10 is worst pain imaginable)

    Time frame: 24 hours, 72 hours

  2. Postoperative rescue medication use

    Opioid and non-opioid pain control medicines needed

    Time frame: 24 hours, 72 hours

07

Study locations

1 site
08

References and documents

Publications

  • Xu HT, Zimmerman J, Bertoch T, Chen L, Chen PJ, Onel E. Efficacy, safety, and pharmacokinetics of CPL-01, an investigational long-acting ropivacaine, in bunionectomy: Results of a phase 2b study. J Foot Ankle Surg. 2025 Mar-Apr;64(2):150-156. doi: 10.1053/j.jfas.2024.09.007. Epub 2024 Sep 19. PubMed 39303759 ↗

Individual participant data

Plan to share: Yes — All IPD necessary for results

Supporting information: Study protocol

Time frame: After approval

Access criteria: As necessary

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Jun 2027, 3 months later.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 3 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Jul 2026 → Mar 2027, primary completion Oct 2026 → Jun 2027 and completion Nov 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 24, 2026
StartEst.
Mar 1, 2027was Jul 2026
Primary completionEst.
Jun 30, 2027was Oct 2026
CompletionEst.
Aug 30, 2027was Nov 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Mar 1, 2027
Oct 21, 2026
Primary completion
Oct 30, 2026→Jun 30, 2027
Oct 21, 2026
Study completion
Nov 28, 2026→Aug 30, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Start date Jul 1, 2026→Mar 1, 2027
    Primary completion Oct 30, 2026→Jun 30, 2027
    Study completion Nov 28, 2026→Aug 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07490496
Lead sponsor
Cali Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Erol Onel, MD
Contact
e.onel@calibiosciences.com
203-837-6500
Todd Bertoch, MD
principal investigator · CenExel

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPL-01

Start the discussion